PERSEPHONE: Duration of trastuzumab with chemotherapy in patients with HER2-positive early breast cancer—Six versus twelve months.
Helena Margaret Earl
Consultant or Advisory Role - Roche
Research Funding - Roche
David A. Cameron
Consultant or Advisory Role - Roche
Honoraria - Roche
Research Funding - Roche
Other Remuneration - Roche
David Miles
No relevant relationships to disclose
Andrew M. Wardley
No relevant relationships to disclose
Emma Ogburn
No relevant relationships to disclose
Anne-Laure Vallier
No relevant relationships to disclose
Shrushma Loi
No relevant relationships to disclose
Louise Hiller
No relevant relationships to disclose
Janet Dunn
No relevant relationships to disclose